141 related articles for article (PubMed ID: 20637317)
1. Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7.
Neunzig I; Drăgan CA; Widjaja M; Schwaninger AE; Peters FT; Maurer HH; Bureik M
Biochim Biophys Acta; 2011 Jan; 1814(1):161-7. PubMed ID: 20637317
[TBL] [Abstract][Full Text] [Related]
2. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
3. Variability of CYP3A7 expression in human fetal liver.
Leeder JS; Gaedigk R; Marcucci KA; Gaedigk A; Vyhlidal CA; Schindel BP; Pearce RE
J Pharmacol Exp Ther; 2005 Aug; 314(2):626-35. PubMed ID: 15845858
[TBL] [Abstract][Full Text] [Related]
4. Identification of CYP3A7 for glyburide metabolism in human fetal livers.
Shuster DL; Risler LJ; Prasad B; Calamia JC; Voellinger JL; Kelly EJ; Unadkat JD; Hebert MF; Shen DD; Thummel KE; Mao Q
Biochem Pharmacol; 2014 Dec; 92(4):690-700. PubMed ID: 25450675
[TBL] [Abstract][Full Text] [Related]
5. Helices F-G are important for the substrate specificities of CYP3A7.
Torimoto N; Ishii I; Toyama K; Hata M; Tanaka K; Shimomura H; Nakamura H; Ariyoshi N; Ohmori S; Kitada M
Drug Metab Dispos; 2007 Mar; 35(3):484-92. PubMed ID: 17178770
[TBL] [Abstract][Full Text] [Related]
6. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta.
Schuetz JD; Kauma S; Guzelian PS
J Clin Invest; 1993 Aug; 92(2):1018-24. PubMed ID: 8349787
[TBL] [Abstract][Full Text] [Related]
7. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
8. Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast.
Yan Q; Machalz D; Zöllner A; Sorensen EJ; Wolber G; Bureik M
Biochem Pharmacol; 2017 Dec; 146():174-187. PubMed ID: 28951277
[TBL] [Abstract][Full Text] [Related]
9. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells.
Ohmori S; Nakasa H; Asanome K; Kurose Y; Ishii I; Hosokawa M; Kitada M
Biochim Biophys Acta; 1998 May; 1380(3):297-304. PubMed ID: 9555064
[TBL] [Abstract][Full Text] [Related]
10. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers.
Rodríguez-Antona C; Jande M; Rane A; Ingelman-Sundberg M
Clin Pharmacol Ther; 2005 Apr; 77(4):259-70. PubMed ID: 15903124
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers.
Hakkola J; Raunio H; Purkunen R; Saarikoski S; Vähäkangas K; Pelkonen O; Edwards RJ; Boobis AR; Pasanen M
Biol Neonate; 2001; 80(3):193-201. PubMed ID: 11585982
[TBL] [Abstract][Full Text] [Related]
12. Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors.
Betts S; Björkhem-Bergman L; Rane A; Ekström L
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):261-6. PubMed ID: 25689036
[TBL] [Abstract][Full Text] [Related]
13. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
Ghassabian S; Rawling T; Zhou F; Doddareddy MR; Tattam BN; Hibbs DE; Edwards RJ; Cui PH; Murray M
Biochem Pharmacol; 2012 Jul; 84(2):215-23. PubMed ID: 22513143
[TBL] [Abstract][Full Text] [Related]
14. A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1.
Rodriguez-Antona C; Axelson M; Otter C; Rane A; Ingelman-Sundberg M
J Biol Chem; 2005 Aug; 280(31):28324-31. PubMed ID: 15937338
[TBL] [Abstract][Full Text] [Related]
15. Engineering of human CYP3A enzymes by combination of activating polymorphic variants.
Neunzig I; Widjaja M; Drăgan CA; Peters FT; Maurer HH; Bureik M
Appl Biochem Biotechnol; 2012 Oct; 168(4):785-96. PubMed ID: 22899011
[TBL] [Abstract][Full Text] [Related]
16. CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids.
Nakamura H; Torimoto N; Ishii I; Ariyoshi N; Nakasa H; Ohmori S; Kitada M
Drug Metab Dispos; 2003 Apr; 31(4):432-8. PubMed ID: 12642469
[TBL] [Abstract][Full Text] [Related]
17. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
18. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
[TBL] [Abstract][Full Text] [Related]
19. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.
Stevens JC
Drug Discov Today; 2006 May; 11(9-10):440-5. PubMed ID: 16635807
[TBL] [Abstract][Full Text] [Related]
20. Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus.
Ohmori S; Fujiki N; Nakasa H; Nakamura H; Ishii I; Itahashi K; Kitada M
Res Commun Mol Pathol Pharmacol; 1998 Apr; 100(1):15-28. PubMed ID: 9644715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]